Title
Lung Cancer Surveillance After Definitive Curative-Intent Therapy
Authoring Organization
Publication Month/Year
December 12, 2019
Last Updated Month/Year
October 2, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non–small-cell lung cancer (NSCLC) and SCLC.
Target Patient Population
Patients with curatively treated stage I-III NSCLC and SCLC.
Target Provider Population
Medical, surgical, and radiation oncologists; oncology nurses and physician assistants; pulmonologists; radiologists; general practitioners
PICO Questions
What should be the frequency of surveillance imaging?
What is the optimal imaging modality?
Are there any patient factors such as performance status or age limits that would preclude surveillance?
Is there a role for circulating biomarkers in surveillance?
What is the role of brain magnetic resonance imaging (MRI) for surveillance in curatively treated NSCLC and SCLC?
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Radiology services
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Management
Diseases/Conditions (MeSH)
D002289 - Carcinoma, Non-Small-Cell Lung
Keywords
non-small cell lung cancer, non-small-cell lung carcinoma (NSCLC), Non Small Cell Lung Cancer, non_small_cell_lung_cancer
Source Citation
DOI: 10.1200/JCO.19.02748 Journal of Clinical Oncology